Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
16-30 of 301
Modern Approaches to Long-Term Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast CancerModern Approaches to Long-Term Metastatic Breast Cancer Care
Genomic Profile of ER+ HER2- Metastatic Invasive Lobular Carcinoma
Project Oncology®Genomic Profile of ER+ HER2- Metastatic Invasive Lobular Carcinoma
Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
Project Oncology®Evaluating Post-CDK4/6 Therapy in PIK3CA-Mutated Metastatic Breast Cancer
Addressing Unmet Needs in Metastatic Uveal Melanoma
CME/CEAddressing Unmet Needs in Metastatic Uveal Melanoma
The Metabolic Roots of Early-Onset Colorectal Cancer
Project Oncology®The Metabolic Roots of Early-Onset Colorectal Cancer
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
CME/CEPatients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL
- advertisement
ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Project Oncology®ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Project Oncology®Clinical Stability Post-Tovorafenib in Pediatric Low-Grade Glioma: FIREFLY-1 Results
Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
Project Oncology®Evaluating PARP and ER Targeting in ER+/HER2– Breast Cancer
From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Project Oncology®From Resistance to Response: Evolving Treatment Pathways in HR+ Breast Cancer
Tracking Tumor Resistance in Metastatic Breast Cancer Care
On the Frontlines of Metastatic Breast CancerTracking Tumor Resistance in Metastatic Breast Cancer Care
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
AudioAbstractsOptimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
- advertisement
Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Project Oncology®Adjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
Project Oncology®Tracking Lineage Infidelity in Pediatric B-ALL: New Insights From ASH
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
MinuteCE®The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
